Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hearing loss class labeling for ED drugs

Executive Summary

FDA is updating labeling for phosphodiesterase type 5 inhibitors to highlight the risk of sudden hearing loss, though the agency is not asserting a causal link. The drug class includes the erectile dysfunction drugs Cialis, Levitra and Viagra and the pulmonary arterial hypertension treatment Revatio (sildenafil citrate). Viagra (sildenafil citrate) labeling previously listed "deafness" and "tinnitus" in the Adverse Reactions section, but Levitra (vardenafil) and Cialis (tadalafil) labeling did not include those risks. Now labeling will be consistent across the PDE-5 inhibitor class, including the addition of information about hearing loss in the Precautions section. FDA identified 29 postmarketing reports of sudden hearing loss in its Adverse Events Reporting System, the agency says Oct. 19...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS048912

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel